Your session is about to expire
← Back to Search
Pembrolizumab for Fast-Growing Cancers
Study Summary
This trial will be testing whether an antibody that blocks negative signals to T cells can help treat patients with a type of cancer that is known to grow and spread quickly.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 65 Patients • NCT02085070Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have colon cancer and have undergone at least two treatments.I have not received a live vaccine within 4 weeks around my MK-3475 dose, except for the flu shot.I have not had major surgery in the last 4 weeks.I use oxygen at home.I am currently taking steroids that affect my whole body.I haven't taken IL-2, interferon, other immunotherapies, immunosuppressants, investigational drugs, or steroids in the last week.I have interstitial lung disease.I haven't taken any growth factor medications in the last 2 weeks.My tumor is stable and has a high number of mutations.I have had at least one treatment for my cancer.I do not have any severe illnesses that could interfere with the study.I have previously been treated with specific immune system targeting drugs.I agree to undergo a biopsy of my cancer.I have cancer that has spread to my brain or surrounding membranes.I have a history of HIV, hepatitis B, or hepatitis C.I haven't had chemotherapy or biological therapy in the last 2 weeks.I have received an organ or tissue transplant from another person.My condition is getting worse.I need other cancer treatments while in this study.I have not had radiation in the last 2 weeks.I have a history of an autoimmune disease like Crohn's, lupus, or rheumatoid arthritis.I have a primary brain tumor.I am fully active or can carry out light work.My organ functions are within normal ranges according to specific tests.My cancer can be measured by tests.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: MSI (Microsatellite Unstable) Negative with Mutator Phenotype
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
What potential side effects has MK-3475 demonstrated in clinical trials?
"Considering the Phase 2 status of MK-3475 (a monoclonal antibody that interferes with negative signalling to T cells), our team assigned it a score of 2 on the safety scale. This is due to there being some evidence in support of its safety but no data showing efficacy."
Is enrollment still open for the current research project?
"According to clinicaltrials.gov, this medical trial is no longer enrolling participants after being posted on the 25th of January 2018 and updated March 3rd 2022. Nonetheless, there are 3335 other trials currently open for recruitment in its place."
What is the sample size of this therapeutic investigation?
"This clinical trial is not presently accruing patients. As of March 3rd 2022, the most recent edit to the study was made on January 25th 2018. For those seeking other research opportunities, there are 2374 cancer studies and 961 MK-3475 (an Antibody That Blocks Negative Signals to T Cells) related trials actively recruiting participants."
Have any prior investigations explored the efficacy of MK-3475 as an inhibitor of inhibitory signals to T Cells?
"Currently, 961 studies involving MK-3475 (an Antibody That Blocks Negative Signals to T Cells) are underway with 122 of these trials in their terminal phase. While numerous research institutes in Houston, Texas have launched investigations into this antibody, there are 35727 sites across the globe engaging in related research."
How many medical centers are currently offering this trial?
"Seven medical sites are enrolling participants for this trial, with Ohio State University in Columbus, Memorial Sloan Kettering Cancer Center in New york City, and Dana-Farber Cancer Institute in Boston being the most prominent. Additionally there are 4 other clinical hubs taking part."
For what maladies is MK-3475 (an Antibody That Blocks Negative Signals to T Cells) commonly administered?
"MK-3475, an antibody that prevents the inhibition of T cells, can be used to treat malignant neoplasms, inoperable melanomas and microsatellite instability high cases."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger